{"id":"W4313416609","doi":"10.21037/jgo-22-86","title":"A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal of Gastrointestinal Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; Juravinski Cancer Centre; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Trametinib; MEK inhibitor; Progressive disease; KRAS; Internal medicine; Clinical endpoint; Adverse effect; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Clinical trial; Gastroenterology; Progression-free survival; Concomitant; Gemcitabine; Chemotherapy; Surgery; Kinase; MAPK/ERK pathway; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001680037,0.001703835,0.002180085,0.0003810564,0.0003469204,0.00100215,0.0006602546,0.001138795,0.006037204],"category_scores_gemma":[0.0009883135,0.0006514926,0.001139135,0.0003812646,0.0007669206,0.0008543989,0.0004846908,0.002690135,0.001188336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007828129,"about_ca_system_score_gemma":0.001470693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007717332,"about_ca_topic_score_gemma":0.001857274,"domain_scores_codex":[0.9995334,0.0002462687,0.00002824712,0.00008038939,0.00003356687,0.00007805812],"domain_scores_gemma":[0.9993766,0.0001132751,0.0001183106,0.00005054373,0.00003177691,0.000309498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9140721,0.02227349,0.002880844,0.0006473182,0.0007744363,0.000114329,0.0001201155,0.002119863,0.00961055,0.000155886,0.00198631,0.04524472],"study_design_scores_gemma":[0.8515463,0.141296,0.003903125,0.00002222855,0.0001846,0.0001341529,0.00002972422,0.0009642892,0.0008071624,0.0001027601,0.0009957886,0.00001395427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921677,0.001501285,0.0003043529,0.00044205,0.0001602795,0.002471904,0.0008187724,0.00008019934,0.002053496],"genre_scores_gemma":[0.9882044,0.001341539,0.001248049,0.0006189726,0.000157298,0.002930174,0.001765324,0.00002150533,0.003712826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006037204,"threshold_uncertainty_score":0.02019644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02136824873145324,"score_gpt":0.3344853763190478,"score_spread":0.3131171275875946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}